Cassava Sciences, Inc. (SAVA)
USD 1.3
(-0.38%)
USD 1.3
(-0.38%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -105.95 Million USD | -32.41% |
| 2022 | -80.02 Million USD | -143.46% |
| 2021 | -32.86 Million USD | -409.9% |
| 2020 | -6.44 Million USD | -29.99% |
| 2019 | -4.95 Million USD | 25.56% |
| 2018 | -6.66 Million USD | 44.25% |
| 2017 | -11.94 Million USD | 20.11% |
| 2016 | -14.95 Million USD | -5.32% |
| 2015 | -14.2 Million USD | -14.23% |
| 2014 | -12.43 Million USD | -139.64% |
| 2013 | 31.36 Million USD | 904.85% |
| 2012 | -3.89 Million USD | -10.9% |
| 2011 | -3.51 Million USD | 74.36% |
| 2010 | -13.7 Million USD | -102.89% |
| 2009 | -6.75 Million USD | -177.53% |
| 2008 | 8.71 Million USD | -14.33% |
| 2007 | 10.16 Million USD | 1938.88% |
| 2006 | -553 Thousand USD | 98.31% |
| 2005 | -32.71 Million USD | 16.03% |
| 2004 | -38.96 Million USD | -75.1% |
| 2003 | -22.25 Million USD | -231.51% |
| 2002 | 16.91 Million USD | 197.71% |
| 2001 | -17.31 Million USD | 14.73% |
| 2000 | -20.3 Million USD | -335.78% |
| 1999 | -4.65 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -67.2 Million USD | -237.12% |
| 2024 Q1 | -19.93 Million USD | 12.53% |
| 2023 Q2 | -28.77 Million USD | -6.97% |
| 2023 Q3 | -27.87 Million USD | 3.12% |
| 2023 Q4 | -22.78 Million USD | 18.26% |
| 2023 FY | -105.95 Million USD | -32.41% |
| 2023 Q1 | -26.9 Million USD | -28.5% |
| 2022 Q3 | -21.34 Million USD | -7.17% |
| 2022 FY | -80.02 Million USD | -143.46% |
| 2022 Q1 | -17.82 Million USD | -23.38% |
| 2022 Q4 | -20.93 Million USD | 1.91% |
| 2022 Q2 | -19.91 Million USD | -11.76% |
| 2021 Q3 | -9.75 Million USD | -89.82% |
| 2021 Q2 | -5.13 Million USD | -45.43% |
| 2021 Q1 | -3.53 Million USD | -34.64% |
| 2021 FY | -32.86 Million USD | -409.9% |
| 2021 Q4 | -14.44 Million USD | -48.1% |
| 2020 Q3 | -1.43 Million USD | -23.56% |
| 2020 FY | -6.44 Million USD | -29.99% |
| 2020 Q2 | -1.16 Million USD | 4.83% |
| 2020 Q1 | -1.22 Million USD | 22.46% |
| 2020 Q4 | -2.62 Million USD | -82.6% |
| 2019 Q2 | -1.15 Million USD | 20.54% |
| 2019 Q4 | -1.57 Million USD | -102.31% |
| 2019 Q1 | -1.45 Million USD | -93.47% |
| 2019 FY | -4.95 Million USD | 25.56% |
| 2019 Q3 | -779 Thousand USD | 32.44% |
| 2018 Q4 | -750 Thousand USD | 41.59% |
| 2018 FY | -6.66 Million USD | 44.25% |
| 2018 Q3 | -1.28 Million USD | 47.83% |
| 2018 Q2 | -2.46 Million USD | -13.57% |
| 2018 Q1 | -2.16 Million USD | 10.57% |
| 2017 FY | -11.94 Million USD | 20.11% |
| 2017 Q2 | -4.16 Million USD | -50.72% |
| 2017 Q1 | -2.76 Million USD | -8.69% |
| 2017 Q3 | -2.59 Million USD | 37.69% |
| 2017 Q4 | -2.42 Million USD | 6.66% |
| 2016 FY | -14.95 Million USD | -5.32% |
| 2016 Q3 | -3.54 Million USD | -16.33% |
| 2016 Q2 | -3.04 Million USD | 47.78% |
| 2016 Q4 | -2.54 Million USD | 28.18% |
| 2016 Q1 | -5.82 Million USD | -28.56% |
| 2015 Q3 | -3.68 Million USD | -8.83% |
| 2015 Q2 | -3.38 Million USD | -30.52% |
| 2015 Q4 | -4.53 Million USD | -23.01% |
| 2015 FY | -14.2 Million USD | -14.23% |
| 2015 Q1 | -2.59 Million USD | -19.75% |
| 2014 Q1 | -3.46 Million USD | -110.53% |
| 2014 FY | -12.43 Million USD | -139.64% |
| 2014 Q3 | -3.54 Million USD | -8.84% |
| 2014 Q2 | -3.25 Million USD | 5.98% |
| 2014 Q4 | -2.16 Million USD | 38.87% |
| 2013 Q2 | -319 Thousand USD | 27.99% |
| 2013 Q1 | -443 Thousand USD | 75.95% |
| 2013 FY | 31.36 Million USD | 904.85% |
| 2013 Q4 | 32.9 Million USD | 4340.08% |
| 2013 Q3 | -776 Thousand USD | -143.26% |
| 2012 Q1 | -148 Thousand USD | 74.66% |
| 2012 Q2 | -253 Thousand USD | -70.95% |
| 2012 Q4 | -1.84 Million USD | -11.3% |
| 2012 FY | -3.89 Million USD | -10.9% |
| 2012 Q3 | -1.65 Million USD | -554.15% |
| 2011 Q3 | -1.02 Million USD | 28.36% |
| 2011 FY | -3.51 Million USD | 74.36% |
| 2011 Q1 | -479 Thousand USD | 94.96% |
| 2011 Q2 | -1.42 Million USD | -198.12% |
| 2011 Q4 | -584 Thousand USD | 42.91% |
| 2010 Q4 | -9.51 Million USD | -505.03% |
| 2010 Q2 | -1.25 Million USD | 7.99% |
| 2010 Q1 | -1.36 Million USD | 18.13% |
| 2010 FY | -13.7 Million USD | -102.89% |
| 2010 Q3 | -1.57 Million USD | -25.26% |
| 2009 Q3 | -2.28 Million USD | -753.73% |
| 2009 FY | -6.75 Million USD | -177.53% |
| 2009 Q2 | -268 Thousand USD | 89.42% |
| 2009 Q4 | -1.66 Million USD | 27.19% |
| 2009 Q1 | -2.53 Million USD | 11.87% |
| 2008 Q4 | -2.87 Million USD | -120.8% |
| 2008 FY | 8.71 Million USD | -14.33% |
| 2008 Q3 | 13.81 Million USD | 638.77% |
| 2008 Q2 | -2.56 Million USD | -863.1% |
| 2008 Q1 | 336 Thousand USD | 120.53% |
| 2007 Q4 | -1.63 Million USD | -408.29% |
| 2007 Q1 | 10.35 Million USD | 216.15% |
| 2007 Q3 | 531 Thousand USD | -42.22% |
| 2007 Q2 | 919 Thousand USD | -91.13% |
| 2007 FY | 10.16 Million USD | 1938.88% |
| 2006 Q4 | -8.91 Million USD | -240.34% |
| 2006 Q2 | 1.5 Million USD | 200.6% |
| 2006 Q3 | 6.35 Million USD | 321.01% |
| 2006 Q1 | 502 Thousand USD | 113.75% |
| 2006 FY | -553 Thousand USD | 98.31% |
| 2005 Q4 | -3.65 Million USD | 60.51% |
| 2005 Q1 | -9.16 Million USD | 6.84% |
| 2005 FY | -32.71 Million USD | 16.03% |
| 2005 Q2 | -10.65 Million USD | -16.34% |
| 2005 Q3 | -9.24 Million USD | 13.21% |
| 2004 FY | -38.96 Million USD | -75.1% |
| 2004 Q2 | -9.28 Million USD | 10.98% |
| 2004 Q1 | -10.43 Million USD | -50.46% |
| 2004 Q3 | -9.4 Million USD | -1.3% |
| 2004 Q4 | -9.83 Million USD | -4.52% |
| 2003 Q3 | -6.09 Million USD | -36.43% |
| 2003 Q2 | -4.46 Million USD | 6.14% |
| 2003 Q4 | -6.93 Million USD | -13.8% |
| 2003 FY | -22.25 Million USD | -231.51% |
| 2003 Q1 | -4.75 Million USD | -116.69% |
| 2002 Q1 | -4.32 Million USD | 29.14% |
| 2002 Q4 | 28.5 Million USD | 966.77% |
| 2002 Q3 | -3.28 Million USD | -182.63% |
| 2002 FY | 16.91 Million USD | 197.71% |
| 2002 Q2 | 3.98 Million USD | 192.12% |
| 2001 Q2 | -3.91 Million USD | -19.16% |
| 2001 Q1 | -3.28 Million USD | 22.02% |
| 2001 Q3 | -4 Million USD | -2.29% |
| 2001 Q4 | -6.09 Million USD | -52.12% |
| 2001 FY | -17.31 Million USD | 14.73% |
| 2000 Q4 | -4.21 Million USD | 32.92% |
| 2000 Q3 | -6.28 Million USD | -67.83% |
| 2000 FY | -20.3 Million USD | -335.78% |
| 2000 Q2 | -3.74 Million USD | -3068.16% |
| 2000 Q1 | -118.25 Thousand USD | 0.0% |
| 1999 FY | -4.65 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 55.331% |
| Alkermes plc | 414.12 Million USD | 125.586% |
| Agenus Inc. | -159.54 Million USD | 33.59% |
| Aptorum Group Limited | -10.52 Million USD | -906.877% |
| Ardelyx, Inc. | -63.27 Million USD | -67.452% |
| Dyadic International, Inc. | -8.22 Million USD | -1187.489% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -8789.01% |
| Lantern Pharma Inc. | -17.87 Million USD | -492.681% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | -427.417% |
| Novavax, Inc. | -566.51 Million USD | 81.297% |
| Janux Therapeutics, Inc. | -72.97 Million USD | -45.188% |
| Pyxis Oncology, Inc. | -82.19 Million USD | -28.908% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | -445.649% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | -903.096% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | -99.443% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 72.153% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -335.918% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | -179.799% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 17.855% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | -26.269% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -504.122% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | -140.757% |
| Clearside Biomedical, Inc. | -24.84 Million USD | -326.489% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 23.789% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 62.45% |
| AlloVir, Inc. | -181.33 Million USD | 41.567% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 48.314% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -262.147% |
| Bicycle Therapeutics plc | -189.94 Million USD | 44.217% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 38.319% |
| ChromaDex Corporation | -5.59 Million USD | -1792.427% |
| Chimerix, Inc. | -93.06 Million USD | -13.853% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -135.056% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 8.704% |
| CRISPR Therapeutics AG | -222.53 Million USD | 52.387% |
| Precision BioSciences, Inc. | -43.73 Million USD | -142.265% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 44.383% |
| Fortress Biotech, Inc. | -142.34 Million USD | 25.562% |
| Fortress Biotech, Inc. | -142.34 Million USD | 25.562% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | -8.458% |
| ImmuCell Corporation | -5.74 Million USD | -1743.347% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 21.18% |
| Immix Biopharma, Inc. | -16.14 Million USD | -556.442% |
| Incyte Corporation | 620.52 Million USD | 117.075% |
| Innoviva, Inc. | 176.7 Million USD | 159.961% |
| IO Biotech, Inc. | -91.44 Million USD | -15.872% |
| Jaguar Health, Inc. | -34.29 Million USD | -208.994% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 37.651% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 987.263% |
| ContextLogic Inc. | -328 Million USD | 67.696% |
| MiMedx Group, Inc. | 37.11 Million USD | 385.475% |
| MEI Pharma, Inc. | 14.54 Million USD | 828.627% |
| NextCure, Inc. | -67.63 Million USD | -56.655% |
| Onconetix, Inc. | -36.03 Million USD | -194.042% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | -154.008% |
| Opthea Limited | -191.84 Million USD | 44.769% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -3750.427% |
| Vaxcyte, Inc. | -468.04 Million USD | 77.362% |
| PDS Biotechnology Corporation | -43.04 Million USD | -146.153% |
| Precigen, Inc. | -88.92 Million USD | -19.156% |
| Pharming Group N.V. | -4.87 Million USD | -2071.453% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 36.671% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | -256.086% |
| PureTech Health plc | -146.19 Million USD | 27.525% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | -417.09% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 55.026% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -335.918% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 61.33% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | -261.566% |
| Acelyrin, Inc. | -422.06 Million USD | 74.896% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -821594.401% |
| Summit Therapeutics Inc. | -89.73 Million USD | -18.076% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | -185.876% |
| Senti Biosciences, Inc. | -92.72 Million USD | -14.268% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 7.681% |
| Elevation Oncology, Inc. | -45.44 Million USD | -133.154% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | -209.21% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -2587.867% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -3250.949% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | -220.878% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -1146.406% |
| Wave Life Sciences Ltd. | -67.99 Million USD | -55.828% |
| Seer, Inc. | -103.46 Million USD | -2.411% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | -61.129% |
| Aadi Bioscience, Inc. | -71.93 Million USD | -47.3% |
| ESSA Pharma Inc. | -32.13 Million USD | -229.734% |
| GlycoMimetics, Inc. | -39.27 Million USD | -169.78% |
| GT Biopharma, Inc. | -13.57 Million USD | -680.473% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 51.667% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | -129.066% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 222.053% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -86.679% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | -105.718% |
| Alzamend Neuro, Inc. | -9.93 Million USD | -966.218% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 78.99% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -1436.054% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | -109.017% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 59.194% |
| Aptose Biosciences Inc. | -52.35 Million USD | -102.378% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | -634.753% |
| Soligenix, Inc. | -7.69 Million USD | -1276.433% |
| Century Therapeutics, Inc. | -146.54 Million USD | 27.697% |
| Kura Oncology, Inc. | -165.8 Million USD | 36.095% |
| TScan Therapeutics, Inc. | -93.45 Million USD | -13.374% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | -1173.675% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -4169.638% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -1534.13% |
| Autolus Therapeutics plc | -195.02 Million USD | 45.671% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | -25.16% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | -43.842% |
| Eterna Therapeutics Inc. | -21.13 Million USD | -401.334% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 53.33% |
| GRI Bio, Inc. | -11.38 Million USD | -830.508% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -2246.406% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 19.236% |
| IGM Biosciences, Inc. | -263.46 Million USD | 59.783% |
| INmune Bio, Inc. | -29.74 Million USD | -256.266% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 4.211% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -178.283% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -563.087% |
| Entero Therapeutics, Inc. | -15.77 Million USD | -571.854% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | -73.421% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 1.456% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 61.611% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 47.856% |
| Verastem, Inc. | -92.08 Million USD | -15.066% |
| Abeona Therapeutics Inc. | -47.13 Million USD | -124.795% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 42.46% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 10.494% |
| Histogen Inc. | -10.64 Million USD | -895.556% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | -584.832% |
| Surrozen, Inc. | -45.78 Million USD | -131.448% |
| Organovo Holdings, Inc. | -15.08 Million USD | -602.353% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -1981.573% |
| Ovid Therapeutics Inc. | -59.28 Million USD | -78.735% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -106.568% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | -319.134% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | -1288.172% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 38.139% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | -118.703% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | -35.486% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | -596.134% |
| Apollomics, Inc. | -54.83 Million USD | -93.232% |
| Amarin Corporation plc | -67.58 Million USD | -56.769% |
| Mesoblast Limited | -58.79 Million USD | -80.217% |
| Turnstone Biologics Corp. | -59.03 Million USD | -79.491% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 35.989% |
| Synaptogenix, Inc. | -8.31 Million USD | -1174.463% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | -626.429% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | -15.559% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -2111.369% |
| Monopar Therapeutics Inc. | -8.83 Million USD | -1099.798% |
| Exelixis, Inc. | 170.88 Million USD | 162.005% |
| Better Therapeutics, Inc. | -38.26 Million USD | -176.925% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 31.668% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 79.51% |
| NLS Pharmaceutics AG | -11.8 Million USD | -797.404% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | -1217.561% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -253.272% |
| Gritstone bio, Inc. | -154.63 Million USD | 31.479% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -53.871% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | -518.797% |
| Avid Bioservices, Inc. | -18.67 Million USD | -467.282% |
| Insmed Incorporated | -709.62 Million USD | 85.069% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | -575.325% |
| MediWound Ltd. | -15.29 Million USD | -592.982% |
| OmniAb, Inc. | -69.41 Million USD | -52.634% |
| Alector, Inc. | -151.74 Million USD | 30.172% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 1.876% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -103.185% |
| Zai Lab Limited | -366.57 Million USD | 71.095% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 66.552% |
| Aura Biosciences, Inc. | -84.99 Million USD | -24.668% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 56.84% |
| Immunic, Inc. | -99.22 Million USD | -6.787% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 25.986% |
| Veracyte, Inc. | -85.79 Million USD | -23.5% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 62.402% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -645.651% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -1438.296% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | -463.822% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 118.313% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | -316.285% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 373.071% |
| TG Therapeutics, Inc. | 20.63 Million USD | 613.532% |
| Galecto, Inc. | -39.9 Million USD | -165.523% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -151.835% |
| Fortrea Holdings Inc. | 63.1 Million USD | 267.919% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 24.556% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | -266.913% |
| XBiotech Inc. | -37.51 Million USD | -182.477% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -53.871% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | -57.862% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 1.806% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -312.734% |
| Theravance Biopharma, Inc. | -53.29 Million USD | -98.823% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 81.385% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | -34.991% |
| Vaxxinity, Inc. | -58.28 Million USD | -81.791% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | -2.168% |
| Gain Therapeutics, Inc. | -22.25 Million USD | -376.144% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | -22.613% |
| NexImmune, Inc. | -29.19 Million USD | -262.96% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -1785.312% |
| Marker Therapeutics, Inc. | -14.58 Million USD | -626.66% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 102.618% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | -316.187% |
| Scopus BioPharma Inc. | -11.71 Million USD | -804.465% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 16.61% |
| Ainos, Inc. | -13.2 Million USD | -702.316% |
| Pluri Inc. | -22.15 Million USD | -378.188% |
| Prothena Corporation plc | -191.03 Million USD | 44.536% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 23.241% |
| Celularity Inc. | -192.28 Million USD | 44.896% |
| Rallybio Corporation | -78.93 Million USD | -34.238% |
| Cue Biopharma, Inc. | -52.14 Million USD | -103.181% |
| MeiraGTx Holdings plc | -137.06 Million USD | 22.694% |
| Omeros Corporation | -164.53 Million USD | 35.6% |
| Humacyte, Inc. | -100.04 Million USD | -5.907% |
| Immunocore Holdings plc | -59.64 Million USD | -77.634% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | -470.92% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | -332.778% |
| Blueprint Medicines Corporation | -486.27 Million USD | 78.211% |
| CalciMedica, Inc. | -21.87 Million USD | -384.375% |
| Cabaletta Bio, Inc. | -74.66 Million USD | -41.919% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 19.415% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 38.144% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 67.587% |
| Pulmatrix, Inc. | -14.74 Million USD | -618.84% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | -196.425% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | -19.232% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 79.437% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | -56.855% |
| Cytokinetics, Incorporated | -496.2 Million USD | 78.647% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -207.845% |
| Nutriband Inc. | -4.87 Million USD | -2074.848% |
| Protara Therapeutics, Inc. | -43.61 Million USD | -142.948% |
| Vor Biopharma Inc. | -126.03 Million USD | 15.931% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 102.498% |
| Evogene Ltd. | -26.39 Million USD | -301.489% |
| ProKidney Corp. | -151.52 Million USD | 30.072% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -64.185% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | -1277.453% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 82.555% |
| CorMedix Inc. | -48.95 Million USD | -116.425% |
| BioLineRx Ltd. | -49.69 Million USD | -113.219% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 7.196% |
| Galectin Therapeutics Inc. | -38.07 Million USD | -178.307% |
| Atai Life Sciences N.V. | -125.47 Million USD | 15.553% |
| Renovaro Biosciences Inc. | -81.63 Million USD | -29.787% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | -30.154% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 57.445% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -244.688% |
| MediciNova, Inc. | -9.9 Million USD | -970.244% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 16.155% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -1362.998% |
| GeoVax Labs, Inc. | -26.74 Million USD | -296.206% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 54.294% |
| Biomea Fusion, Inc. | -126.13 Million USD | 15.997% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 69.675% |
| Mereo BioPharma Group plc | -28.41 Million USD | -272.878% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 44.551% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 53.923% |
| Absci Corporation | -115.51 Million USD | 8.274% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -284.083% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 6.122% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 56.245% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | -320.531% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 49.058% |
| Allakos Inc. | -196.05 Million USD | 45.956% |
| Imunon, Inc. | -21.03 Million USD | -403.827% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 4.253% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 198.765% |
| BioAtla, Inc. | -129.68 Million USD | 18.298% |
| NLS Pharmaceutics AG | -11.8 Million USD | -797.404% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -568.794% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 67.67% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | -153.741% |
| XOMA Corporation | -41.84 Million USD | -153.195% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | -0.684% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 12.789% |
| aTyr Pharma, Inc. | -54.91 Million USD | -92.933% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | -21.195% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 38.707% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 58.358% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | -393.604% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | -1190.152% |
| Akari Therapeutics, Plc | -16.8 Million USD | -530.471% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -1198097.903% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 131.388% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -1521.62% |
| UroGen Pharma Ltd. | -65.53 Million USD | -61.678% |
| Sutro Biopharma, Inc. | -89.27 Million USD | -18.682% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -1358.858% |
| Orgenesis Inc. | -53.63 Million USD | -97.548% |
| Entera Bio Ltd. | -8.89 Million USD | -1091.733% |
| GH Research PLC | -41.22 Million USD | -157.04% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | -312.156% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | -27.578% |
| Xencor, Inc. | -138.63 Million USD | 23.573% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -1955.588% |
| Replimune Group, Inc. | -234.77 Million USD | 54.868% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | -393.027% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | -659.44% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -1521.62% |
| Portage Biotech Inc. | -18.25 Million USD | -480.491% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -1362.998% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | -0.949% |
| OncoCyte Corporation | -25.13 Million USD | -321.535% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -837.27% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -824.818% |
| Purple Biotech Ltd. | 22.27 Million USD | 575.762% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | -1310.503% |
| scPharmaceuticals Inc. | -55.39 Million USD | -91.272% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | -460.687% |
| HilleVax, Inc. | -133.34 Million USD | 20.539% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | -779.384% |
| Tharimmune, Inc. | -9.45 Million USD | -1020.619% |
| Genprex, Inc. | -31.07 Million USD | -240.966% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 43.698% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | -237.69% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -13750.588% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -1845.265% |
| OKYO Pharma Limited | -15.74 Thousand USD | -672654.39% |
| Savara Inc. | -60 Million USD | -76.574% |
| Curis, Inc. | -48.33 Million USD | -119.227% |
| Daré Bioscience, Inc. | -30.83 Million USD | -243.571% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -1930.886% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -1356.053% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | -288.833% |
| BeiGene, Ltd. | -1.2 Billion USD | 91.227% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -431.398% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 78.251% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | -13.139% |
| Erasca, Inc. | -141.52 Million USD | 25.132% |
| bluebird bio, Inc. | -244.26 Million USD | 56.622% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -2240.57% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 154.493% |
| DBV Technologies S.A. | -76.43 Million USD | -38.629% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -2240.57% |
| Moderna, Inc. | -4.23 Billion USD | 97.5% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -148.673% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -1565.991% |
| Molecular Templates, Inc. | -10.46 Million USD | -912.393% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | -57.587% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 71.876% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 26.065% |
| Spruce Biosciences, Inc. | -51.99 Million USD | -103.791% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 31.438% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 49.091% |
| MacroGenics, Inc. | -168.24 Million USD | 37.022% |
| RenovoRx, Inc. | -11.39 Million USD | -829.774% |
| Adicet Bio, Inc. | -152.03 Million USD | 30.309% |
| Prime Medicine, Inc. | -191.29 Million USD | 44.61% |
| Aditxt, Inc. | -26.06 Million USD | -306.551% |
| Adagene Inc. | -23.71 Million USD | -346.702% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1349.461% |
| Quantum-Si incorporated | -111.17 Million USD | 4.69% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | -234.798% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -626.84% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 186.84% |
| SciSparc Ltd. | -5.77 Million USD | -1735.389% |
| Vericel Corporation | -6.46 Million USD | -1539.186% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -1123.993% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | -358.3% |
| Generation Bio Co. | -138.56 Million USD | 23.532% |
| Astria Therapeutics, Inc. | -83.03 Million USD | -27.613% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | -22.55% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 56.053% |
| Invivyd, Inc. | -207.78 Million USD | 49.006% |
| Relay Therapeutics, Inc. | -373 Million USD | 71.593% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | -1029.786% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 593.259% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -930.009% |
| 2seventy bio, Inc. | -216.7 Million USD | 51.105% |
| ADMA Biologics, Inc. | 21.63 Million USD | 589.816% |
| Clene Inc. | -40.54 Million USD | -161.364% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | -340.06% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | -93.366% |
| GeoVax Labs, Inc. | -26.74 Million USD | -296.206% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 69.732% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | -188.46% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 759.06% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | -2.175% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -211.62% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 37.774% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 84.516% |
| Evaxion Biotech A/S | -22.19 Million USD | -377.348% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | -28.617% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 52.512% |
| Trevena, Inc. | -35.28 Million USD | -200.264% |
| Surrozen, Inc. | -45.78 Million USD | -131.448% |
| Tyra Biosciences, Inc. | -79.94 Million USD | -32.537% |
| Cingulate Inc. | -22.75 Million USD | -365.557% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 1514.269% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -137.215% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | -1186.832% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | -3.314% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | -44.397% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | -70.695% |
| Clearmind Medicine Inc. | -8.74 Million USD | -1112.135% |
| Kronos Bio, Inc. | -121.83 Million USD | 13.029% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | -39.058% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -3512.599% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -5.088% |
| Statera Biopharma, Inc. | -98.34 Million USD | -7.741% |
| ImmunityBio, Inc. | -362.25 Million USD | 70.75% |
| Korro Bio, Inc. | -84.53 Million USD | -25.342% |
| Kineta, Inc. | -15.72 Million USD | -573.898% |
| BioVie Inc. | -32.17 Million USD | -229.268% |
| Codexis, Inc. | -68.06 Million USD | -55.661% |
| Celularity Inc. | -192.28 Million USD | 44.896% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 52.402% |
| Celcuity Inc. | -66.23 Million USD | -59.983% |
| Virax Biolabs Group Limited | -6.49 Million USD | -1530.993% |
| Cibus, Inc. | -318.88 Million USD | 66.772% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | -146.412% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -213.075% |
| IN8bio, Inc. | -30.33 Million USD | -249.267% |
| Kodiak Sciences Inc. | -277.32 Million USD | 61.793% |
| Annexon, Inc. | -143.72 Million USD | 26.277% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 14.407% |
| Assembly Biosciences, Inc. | -64.64 Million USD | -63.903% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | -351.958% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 70.046% |
| Eyenovia, Inc. | -25.4 Million USD | -317.048% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 424.623% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -1805.016% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | -33.897% |
| Arcellx, Inc. | -89.88 Million USD | -17.887% |
| Cardiff Oncology, Inc. | -45.41 Million USD | -133.324% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 22.776% |
| Regulus Therapeutics Inc. | -31.1 Million USD | -240.599% |
| Moolec Science SA | -6.65 Million USD | -1492.427% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | -73.308% |
| Geron Corporation | -193.94 Million USD | 45.367% |
| LAVA Therapeutics N.V. | -43.25 Million USD | -144.97% |
| Royalty Pharma plc | 1.49 Billion USD | 107.101% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 35.456% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -1035.919% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | -383.94% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 38.021% |
| Humacyte, Inc. | -100.04 Million USD | -5.907% |
| Structure Therapeutics Inc. | -102.77 Million USD | -3.096% |
| 89bio, Inc. | -151.2 Million USD | 29.924% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | -32.228% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | -628.728% |
| Genelux Corporation | -24.16 Million USD | -338.473% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | -212.346% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 38.307% |
| Notable Labs, Ltd. | -14.65 Million USD | -622.911% |
| Liquidia Corporation | -73.38 Million USD | -44.387% |
| Mustang Bio, Inc. | -50.72 Million USD | -108.881% |
| Immunovant, Inc. | -282.7 Million USD | 62.521% |
| Quantum-Si incorporated | -111.17 Million USD | 4.69% |
| Arbutus Biopharma Corporation | -78.1 Million USD | -35.663% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | -398.223% |
| Vera Therapeutics, Inc. | -102.01 Million USD | -3.867% |
| Acasti Pharma Inc. | -11.31 Million USD | -836.678% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | -362.268% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -563.087% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 50.5% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -2787.842% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -566.984% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | -263.402% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | -156.034% |
| PepGen Inc. | -84.76 Million USD | -24.999% |
| Moleculin Biotech, Inc. | -29.63 Million USD | -257.588% |
| United Therapeutics Corporation | 1.18 Billion USD | 108.942% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -362.755% |
| Solid Biosciences Inc. | -104.31 Million USD | -1.574% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | -222.96% |
| Immuneering Corporation | -58.41 Million USD | -81.393% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -1981.573% |
| Silo Pharma, Inc. | -3.85 Million USD | -2648.138% |
| Belite Bio, Inc | -31.66 Million USD | -234.587% |
| XOMA Corporation | -41.84 Million USD | -153.195% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | -56.927% |
| Bionomics Limited | -17.89 Billion USD | 99.408% |
| Apogee Therapeutics, Inc. | -93 Million USD | -13.929% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 396.965% |
| uniQure N.V. | -282.87 Million USD | 62.542% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1349.461% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 18.182% |
| Forte Biosciences, Inc. | -32.48 Million USD | -226.162% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | -1175.245% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | -260.459% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -1805.016% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -645.651% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | -1092.001% |
| Altimmune, Inc. | -95.92 Million USD | -10.454% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -44.171% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 396.965% |
| Compugen Ltd. | -12.99 Million USD | -715.556% |
| Peak Bio, Inc. | -1356.23 USD | -7812512.905% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | -113.606% |
| Benitec Biopharma Inc. | -22.49 Million USD | -371.129% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 56.271% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | -256.206% |
| Zura Bio Limited | -62.63 Million USD | -69.158% |
| PolyPid Ltd. | -22.86 Million USD | -363.362% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | -551.001% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | -256.206% |
| Instil Bio, Inc. | -159.16 Million USD | 33.431% |
| argenx SE | -425.04 Million USD | 75.072% |
| Immunome, Inc. | -109.53 Million USD | 3.262% |
| Compass Therapeutics, Inc. | -50.36 Million USD | -110.387% |
| Verona Pharma plc | -67.83 Million USD | -56.208% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | -306.589% |
| Shattuck Labs, Inc. | -91.95 Million USD | -15.225% |
| CervoMed Inc. | -7.81 Million USD | -1256.181% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | -44.928% |
| Plus Therapeutics, Inc. | -13.32 Million USD | -695.413% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -119.946% |
| Moolec Science SA | -6.65 Million USD | -1492.427% |
| Enveric Biosciences, Inc. | -16.44 Million USD | -544.177% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 21.645% |
| AnaptysBio, Inc. | -164.41 Million USD | 35.554% |
| Design Therapeutics, Inc. | -78.19 Million USD | -35.512% |
| Leap Therapeutics, Inc. | -87.04 Million USD | -21.732% |
| NeurAxis, Inc. | -6.66 Million USD | -1489.873% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | -161.629% |
| Lumos Pharma, Inc. | -36.61 Million USD | -189.389% |
| Achilles Therapeutics plc | -75.25 Million USD | -40.797% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | -306.589% |
| 180 Life Sciences Corp. | -13.47 Million USD | -686.177% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 2154.899% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -3512.599% |
| Nutriband Inc. | -4.87 Million USD | -2074.848% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 4.354% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | -91.089% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | -108.429% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | -60.3% |
| MoonLake Immunotherapeutics | -54.12 Million USD | -95.77% |
| Palisade Bio, Inc. | -13.07 Million USD | -710.689% |
| Tourmaline Bio, Inc. | -45.4 Million USD | -133.339% |
| Beam Therapeutics Inc. | -176.48 Million USD | 39.963% |
| Neurogene Inc. | -55.58 Million USD | -90.628% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 2.929% |
| AEON Biopharma, Inc. | -48.42 Million USD | -118.788% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | -9.562% |
| Sesen Bio, Inc. | -25.9 Million USD | -308.958% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | -26.851% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | -741.804% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 76.994% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | -46.271% |
| Athira Pharma, Inc. | -125.46 Million USD | 15.549% |
| Vaccinex, Inc. | -22.88 Million USD | -362.998% |
| HCW Biologics Inc. | -25.71 Million USD | -312.009% |
| XOMA Corporation | -41.84 Million USD | -153.195% |
| Nektar Therapeutics | -137.42 Million USD | 22.898% |
| Arvinas, Inc. | -401.5 Million USD | 73.61% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -1198097.903% |
| Merus N.V. | -156.54 Million USD | 32.316% |
| Omega Therapeutics, Inc. | -100.26 Million USD | -5.681% |
| Quince Therapeutics, Inc. | -34.62 Million USD | -206.057% |
| Rezolute, Inc. | -70.42 Million USD | -50.458% |
| Clene Inc. | -40.54 Million USD | -161.364% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | -546.928% |
| BeyondSpring Inc. | -23.11 Million USD | -358.41% |
| Synlogic, Inc. | -55.16 Million USD | -92.087% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | -490.981% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -878.908% |
| Peak Bio, Inc. | -1356.23 USD | -7812512.905% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | -161.603% |
| Krystal Biotech, Inc. | -109.72 Million USD | 3.436% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 18.205% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 69.11% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -2132.576% |
| MannKind Corporation | 8.67 Million USD | 1320.984% |
| Ikena Oncology, Inc. | -75.41 Million USD | -40.495% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | -998.341% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | -57.604% |
| Gossamer Bio, Inc. | -183.75 Million USD | 42.339% |
| CohBar, Inc. | -12.38 Million USD | -755.299% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | -108.889% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -284.083% |
| Legend Biotech Corporation | -439.48 Million USD | 75.891% |
| Mural Oncology plc | -194.63 Million USD | 45.562% |
| Biora Therapeutics, Inc. | -67.14 Million USD | -57.808% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -556.273% |
| Disc Medicine, Inc. | -91.12 Million USD | -16.277% |
| Champions Oncology, Inc. | -7.35 Million USD | -1340.416% |
| REGENXBIO Inc. | -268.12 Million USD | 60.483% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -888.572% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -90.037% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | -171.959% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 7.345% |
| Vaxart, Inc. | -83.34 Million USD | -27.128% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | -1143.626% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | -147.597% |
| Cellectis S.A. | -106.62 Million USD | 0.627% |
| Longeveron Inc. | -21.02 Million USD | -403.861% |
| Repare Therapeutics Inc. | -116.22 Million USD | 8.834% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 60.438% |
| Inozyme Pharma, Inc. | -75.64 Million USD | -40.071% |
| Revolution Medicines, Inc. | -487.18 Million USD | 78.251% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -1492.859% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | -141.063% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -42.053% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | -52.161% |
| Anixa Biosciences, Inc. | -11.01 Million USD | -862.283% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 102.46% |
| Denali Therapeutics Inc. | -196.69 Million USD | 46.132% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -1123.993% |
| Veru Inc. | -93.78 Million USD | -12.982% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | -354.186% |
| Cingulate Inc. | -22.75 Million USD | -365.557% |
| Passage Bio, Inc. | -108.38 Million USD | 2.244% |
| Context Therapeutics Inc. | -25.07 Million USD | -322.6% |
| Exicure, Inc. | -14.99 Million USD | -606.568% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 48.581% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | -160.991% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | -990.436% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 42.526% |
| Nuvalent, Inc. | -149.49 Million USD | 29.122% |
| ABVC BioPharma, Inc. | -8.21 Million USD | -1189.562% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | -19.414% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | -410.046% |
| OmniAb, Inc. | -69.41 Million USD | -52.634% |
| Anew Medical, Inc. | -1.3 Million USD | -8045.275% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | -729.669% |
| Lipocine Inc. | -17.93 Million USD | -490.917% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | -54.652% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | -39.139% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -178.283% |
| G1 Therapeutics, Inc. | -39.52 Million USD | -168.062% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | -373.36% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 81.727% |
| Ocugen, Inc. | -65.53 Million USD | -61.69% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | -12.881% |
| Q32 Bio Inc. | -92.1 Million USD | -15.043% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | -394.225% |
| Alumis Inc. Common Stock | -158.17 Million USD | 33.012% |
| Equillium, Inc. | -14.52 Million USD | -629.631% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | -69.787% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -1240.66% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -461.656% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -125.676% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 2.313% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -785.187% |
| Dominari Holdings Inc. | -21.79 Million USD | -386.13% |
| Edesa Biotech, Inc. | -9.22 Million USD | -1048.865% |
| vTv Therapeutics Inc. | -25.5 Million USD | -315.485% |
| Bio-Techne Corporation | 206.68 Million USD | 151.265% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 72.935% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 155.177% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 19.898% |
| Candel Therapeutics, Inc. | -38.39 Million USD | -175.994% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 29.877% |
| Nkarta, Inc. | -131.65 Million USD | 19.516% |
| BioCardia, Inc. | -11.64 Million USD | -809.971% |
| Iterum Therapeutics plc | -47.46 Million USD | -123.218% |